Samsung Epis Holdings (CEO Kim Kyung-ah) held an on-site press briefing in the course of the ‘JP Morgan Healthcare Convention’ in San Francisco, United States on January 14 (native time), disclosing its main enterprise methods and analysis and growth roadmap.
CEO Kim Kyung-ah, who oversees the administration of holding firm Samsung Epis Holdings and its subsidiaries (Samsung Bioepis, EpisNexLab), said, “Based mostly on the achievements in our biosimilar enterprise, which is the corporate’s core basis, we are going to develop our enterprise scope into new drug growth.”
Samsung Bioepis’ biosimilar merchandise are presently launched in additional than 40 international locations worldwide and are producing steady income by steady gross sales quantity growth.
CEO Kim said, “We are going to actively develop our biosimilar portfolio to a complete of 20 varieties by 2030, and we’re presently creating biosimilars for seven extra blockbuster medication (Keytruda, Dupixent, Tremfya, Taltz, Enhertu, Entyvio, Ocrevus).”
Moreover, relating to new drug growth growth, the corporate just lately obtained Investigational New Drug (IND) approval for an antibody-drug conjugate (ADC) new drug candidate (venture title: SBE303), and introduced plans so as to add not less than one new drug candidate in the principle medical stage yearly beginning subsequent yr.
Samsung Epis Holdings has adopted a coverage of pursuing enterprise in phases whereas securing market belief by thorough scientific verification, avoiding short-term outcomes or easy pipeline growth within the new drug growth course of.
In the meantime, Samsung Epis Holdings is establishing new progress engines in numerous enterprise areas, together with pursuing next-generation therapeutic expertise platform analysis and growth enterprise by its newly established subsidiary EpisNexLab.
Samsung Epis Holdings CEO Kim Kyung-ah expressed her ambition, stating, “Utilizing the success in our biosimilar enterprise as a springboard, we are going to totally launch new drug growth to develop right into a Korean-style ‘Massive Pharma’ mannequin acknowledged within the international market, thereby maximizing shareholder worth and main the brand new way forward for Korea’s bio business.”
